Current Edition

diabetes

Novo Nordisk, trying to switch patients to Rybelsus, launches new TV ad

Down with Rybelsus! No, this isn’t a line from “1984,” but rather the new message from Novo Nordisk for its first Rybelsus ad of 2022. …

Continue Reading →
diabetes

Zealand becomes a lesson in the rigors of commercialization as a slow launch triggers 90% staff cut, CEO exit

It wasn’t supposed to be this way. Zealand Pharma should be in the honeymoon glow of its first drug launch with a drug approved less …

Continue Reading →
diabetes

FDA chides Eli Lilly for second misleading ad in 2 months, this time for diabetes blockbuster Trulicity

After neatly wrapping up concerns over a series of Emgality ads last month, Eli Lilly is back in hot water with the FDA’s Office of …

Continue Reading →
diabetes

Lawmakers blast pharma for ‘outrageous’ prices and ‘anticompetitive conduct’ in culmination of 3-year probe

For years, drugmakers have targeted “weaknesses” in the U.S. healthcare system to reap dividends on older meds, The House Oversight Committee said Friday. The “outrageous …

Continue Reading →
Biocon

Viatris launched two versions of its interchangeable insulin biosimilar. Why?

It’s official: Biocon and Viatris have launched their historic interchangeable insulin biosimilar, Semglee. The drug, which references Sanofi’s blockbuster diabetes med Lantus, will roll out …

Continue Reading →
Altasciences

Altasciences Participates in Clinical Trial for Type 1 Diabetes Mellitus

Altasciences is pleased to have partnered with Xeris Pharmaceuticals, a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable …

Continue Reading →
Asia Pacific

Janssen to begin phase 2 clinical trials of Hanmi Pharma’s diabetes drug

US pharmaceutical company Janssen will start carrying out phase 2 clinical trials in the US to evaluate the efficacy and safety of a diabetes drug …

Continue Reading →
BRIGHT study

Sanofi’s Toujeo® met main objective in head-to-head study versus insulin degludec

Sanofi’s Toujeo® met the primary study objective in the first large head-to-head clinical trial1, called BRIGHT study, comparing Toujeo with insulin degludec. Sanofi plans to …

Continue Reading →
clinical trial

Xultophy® reported a better option than basal-bolus insulin therapy to manage type 2 diabetes by participants in the DUAL VII clinical trial

Once-daily Xultophy® (insulin degludec/liraglutide) was a better option to manage diabetes compared to multiple daily injections of insulin (basal-bolus regimen). This was reported by people …

Continue Reading →
clinical

Imcyse continues patient enrolment in its Phase 1b trial in type 1 diabetes

Imcyse, a biotechnology company developing active specific therapies for the treatment of severe chronic diseases, today announces that it began recruiting patients into its multicenter …

Continue Reading →